NEW YORK (GenomeWeb News) – Cell Biosciences on Wednesday said that it had completed the acquisition of Alpha Innotech.
Santa Clara, Calif.-based Cell Biosciences will pay Alpha Innotech's shareholders $1.50 per share, giving the deal a total consideration of $17.9 million.
The firms announced the deal in early September.
Alpha Innotech is based in San Leandro, Calif., and had 2008 revenues of $17.6 million. The firm sells digital imaging systems used for genomic and proteomic research, and has sold more than 10,000 of its systems worldwide. Its products complement Cell Biosciences' CB1000 system, a nanofluidic immunoassay platform for detecting and characterizing oncoproteins and other signaling proteins in ultra-small biological samples.